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SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, 
duration of viral shedding, and infectiousness: a systematic 
review and meta-analysis
Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, Antonia Ho
Summary
Background Viral load kinetics and duration of viral shedding are important determinants for disease transmission. 
We aimed to characterise viral load dynamics, duration of viral RNA shedding, and viable virus shedding of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in various body fluids, and to compare SARS-CoV-2, 
SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) viral dynamics.
Methods In this systematic review and meta-analysis, we searched databases, including MEDLINE, Embase, Europe 
PubMed Central, medRxiv, and bioRxiv, and the grey literature, for research articles published between Jan 1, 2003, 
and June 6, 2020. We included case series (with five or more participants), cohort studies, and randomised controlled 
trials that reported SARS-CoV-2, SARS-CoV, or MERS-CoV infection, and reported viral load kinetics, duration of viral 
shedding, or viable virus. Two authors independently extracted data from published studies, or contacted authors to 
request data, and assessed study quality and risk of bias using the Joanna Briggs Institute Critical Appraisal Checklist 
tools. We calculated the mean duration of viral shedding and 95% CIs for every study included and applied the 
random-effects model to estimate a pooled effect size. We used a weighted meta-regression with an unrestricted 
maximum likelihood model to assess the effect of potential moderators on the pooled effect size. This study 
is registered with PROSPERO, CRD42020181914.
Findings 79 studies (5340 individuals) on SARS-CoV-2, eight studies (1858 individuals) on SARS-CoV, and 
11 studies (799 individuals) on MERS-CoV were included. Mean duration of SARS-CoV-2 RNA shedding was 17·0 days 
(95% CI 15·5–18·6; 43 studies, 3229 individuals) in upper respiratory tract, 14·6 days (9·3–20·0; seven studies, 
260 individuals) in lower respiratory tract, 17·2 days (14·4–20·1; 13 studies, 586 individuals) in stool, and 16·6 days 
(3·6–29·7; two studies, 108 individuals) in serum samples. Maximum shedding duration was 83 days in the upper 
respiratory tract, 59 days in the lower respiratory tract, 126 days in stools, and 60 days in serum. Pooled mean 
SARS-CoV-2 shedding duration was positively associated with age (slope 0·304 [95% CI 0·115–0·493]; p=0·0016). No 
study detected live virus beyond day 9 of illness, despite persistently high viral loads, which were inferred from cycle 
threshold values. SARS-CoV-2 viral load in the upper respiratory tract appeared to peak in the first week of illness, 
whereas that of SARS-CoV peaked at days 10–14 and that of MERS-CoV peaked at days 7–10. 
Interpretation Although SARS-CoV-2 RNA shedding in respiratory and stool samples can be prolonged, duration of 
viable virus is relatively short-lived. SARS-CoV-2 titres in the upper respiratory tract peak in the first week of illness. 
Early case finding and isolation, and public education on the spectrum of illness and period of infectiousness are key 
to the effective containment of SARS-CoV-2.
Funding None.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Viral load kinetics and the duration of viral shedding are 
important determinants for disease transmission. They 
determine the duration of infectiousness, which is a 
critical parameter to inform effective control mea sures 
and disease modelling. Although several studies have 
evaluated severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) shedding, viral load dyn amics and duration 
of viral shedding reported across studies so far have been 
heterogeneous.1 In several case series with serial res-
piratory sampling, peak viral load was observed just 
before, or at the time of, symptom onset.2–4 Viral RNA 
shedding was reported to be persistent in the upper 
respiratory tract and in faeces for more than 1 month after 
illness onset.1 However, the duration of SARS-CoV-2 RNA 
detection has not been well characterised. A compre-
hensive understanding of viral load dynamics, length of 
viral shedding, and how these measures relate to other 
factors, such as age and disease severity, is lacking.
We aimed to characterise the viral load dynamics 
of SARS-CoV-2, duration of viral RNA shedding by 
RT-PCR, and viable virus shedding in various body fluids, 
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and to compare SARS-CoV-2 viral dynamics with those of 
SARS-CoV and Middle East respiratory synd rome 
coronavirus (MERS-CoV).
Methods
Search strategy and selection criteria
We retrieved all English-language research articles 
reporting viral dynamics or the duration of shedding of 
SARS-CoV-2, SARS-CoV, or MERS-CoV in various 
specimens through systematic searches of major 
databases, including MEDLINE, Embase, Europe PubMed 
Central, medRxiv, and bioRxiv, and the grey literature 
from Jan 1, 2003, to June 6, 2020, using medical subject 
headings terms (appendix p 14). We also manually 
screened the references of included original studies to 
obtain additional studies. Studies published before 2003 
were excluded because the first recognised case of 
SARS-CoV was identified in March, 2003.
Studies were eligible if they met the following inclusion 
criteria: report on SARS-CoV-2, SARS-CoV, or MERS-CoV 
infection, and report viral load kinetics, duration of viral 
shedding, or viable virus shedding. We excluded review 
papers; animal studies; studies on environmental 
sampling; case reports and case series with less than 
five participants, due to likely reporting bias; papers in 
which the starting point of viral shedding was not clear 
or reported from post hospital discharge; and modelling 
studies with no original data.
Data extraction
Two authors (MT and OL) screened and retrieved articles 
according to the eligibility criteria. Four reviewers (MT, 
OL, JS, and MC) reviewed full-text articles and selected 
articles to be included. From each study, the following 
variables were extracted as a minimum: name of first 
author, year of publication, city and country, sample size, 
median age, sex ratio, time from symptom onset to viral 
clearance detected by RT-PCR and culture in different 
specimens, and longest reported time to viral clearance. 
If these data were not reported, we also contacted the 
See Online for appendix
Research in context
Evidence before this study
Understanding when patients are most infectious and 
the duration of infectiousness are of critical importance to 
controlling the COVID-19 pandemic. The duration of RNA 
detection across human coronaviruses has not been well 
characterised, and comprehensive understanding about viral 
load dynamics and the duration of viral shedding in severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
is lacking. We retrieved all articles reporting the dynamics 
and the duration of SARS-CoV-2, SARS-CoV, and Middle East 
respiratory syndrome coronavirus (MERS-CoV) shedding 
in various specimens through systematic searches of major 
databases. Our research identified publications that included 
terms related to viral dynamics and viral shedding. 
We included case series, cohort studies, and randomised 
controlled trials in which the viral dynamics or the duration 
of viral shedding was reported. We excluded case reports, 
case series with fewer than five patients, and studies that 
did not have a clear time of symptom onset.
Added value of this study
To our knowledge, this is the first systematic review and 
meta-analysis that has examined and compared the 
viral dynamics of the three highly pathogenic human 
coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. 
The results provide a comprehensive understanding 
regarding their viral kinetics and duration of shedding. 
Mean SARS-CoV-2 RNA shedding duration was 17·0 days 
(maximum shedding duration 83 days) in upper respiratory 
tract, 14·6 days (maximum 59 days) in lower respiratory tract, 
17·2 days (maximum 35 days) in stool, and 16·6 days 
(maximum 60 days) in serum samples. Pooled mean 
SARS-CoV-2 shedding duration was positively associated with 
age. No study detected live virus beyond day 9 of illness, 
despite persistently high viral loads. SARS-CoV-2 viral load in 
the upper respiratory tract appeared to peak in the first week 
of illness, whereas SARS-CoV and MERS-CoV peaked later. 
Several studies reported similar viral loads at the start of 
infection among asymptomatic and symptomatic patients 
infected with SARS-CoV-2; however, most studies 
demonstrated faster viral clearance in asymptomatic 
individuals, as also seen in MERS-CoV, suggesting a shorter 
infectious period but with similar potential transmissibility at 
the onset of infection.
Implications of all the available evidence
Our study shows that despite evidence of prolonged 
SARS-CoV-2 RNA shedding in respiratory and stool samples, 
viable virus appears to be short-lived. Therefore, RNA detection 
cannot be used to infer infectiousness. High titres of 
SARS-CoV-2 are detected early in the disease course, with 
an early peak observed at the time of symptom onset to 
day 5 of illness; this finding probably explains the efficient 
spread of SARS-CoV-2 compared with SARS-CoV and 
MERS-CoV. This has important implications for SARS-CoV-2 
transmission in the community and hospital setting, 
emphasising the importance of early case finding and prompt 
isolation as well as public education about the spectrum of 
illness. Our study shows that isolation practices should be 
commenced with the start of first symptoms, which can include 
mild and atypical symptoms, preceding typical symptoms of 
COVID-19 such as cough and fever. However, given the 
potential delays in isolation of patients, even the early 
detection and isolation strategy might not be fully effective 
in containing SARS-CoV-2.
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authors to request the data. If available, we extracted data 
on peak viral load, clinical outcome, and reported factors 
associated with duration of viral shedding.
Two authors (OL and JS) independently assessed study 
quality and risk of bias using the Joanna Briggs Institute 
Critical Appraisal Checklist tools,5 which comprise stan-
dardised checklists, for the different study designs 
included in this review. Any disagreements regarding 
grading of quality were resolved through discussion with 
a third author (MC).
Data analysis
For every study included, we calculated the mean duration 
of viral shedding and 95% CIs. We applied the random-
effects model to estimate a pooled effect size. We 
generated forest plots to show the detailed representation 
of all studies based on the effect size and 95% CI. If not 
rep orted, we derived means and SDs from sample size, 
and median, IQR, minimum, and maximum values.6 Het-
ero geneity between studies was quantified by the I² index 
and Cochran’s Q test. We did not assess publication bias 
because usual appraisal methods are uninformative when 
meta-analy sed studies do not include a test of significance. 
We used a weighted meta-regression with an unrestricted 
max imum likelihood model to assess the effect of 
potential moderators on the pooled effect size (p<0·05 
was considered to be significant). The eligibility criterion 
for meta-regression was the presence of at least ten studies 
(referring to one virus) for each covariate. All statistical 
analyses were done with Comprehensive Meta-Analysis 
(version 3) software (Biostat, Englewood, NJ, USA).
This systematic review is registered with PROSPERO, 
CRD42020181914, and will be updated periodically.
Role of the funding source 
There was no funding source for this study. The corres-
ponding author and senior author (AH) had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The systematic search identified 1486 potentially relevant 
articles. 350 articles were retrieved for full-text review. After 
reviewing the eligibility criteria, 79 studies (5340 individuals) 
on SARS-CoV-2,2–4,7–82 eight (1858 individuals) on SARS-
CoV,83–90 and 11 (799 individuals) on MERS-CoV91–101 were 
included (figure 1).
Of the 79 papers included, 58 studies were done in 
China (appendix pp 1–4).2,10–12,14–17,19–21,23–28,35–41,43,44,48–50,52–63,65–73,75–82 
73 studies included only patients who were admitted to 
hospital.3,4,7–29,31,32,34–49,52–54,56–82 Six studies reported viral load 
dynamics exclusively in children (age younger than 
16 years).7–12 Two additional studies included children, but 
data on viral load dynamics were presented in aggregate 
with adults.13,14
61 studies reported median or maximum viral RNA 
shedding in at least one body fluid and were eligible 
for quan titative analysis,3,4,7,9–12,14–17,19–22,24,25,27–30,34–43,45,47,48,50,51,53,54,57–65, 
67–76,78–80,82 and six studies provided duration of shedding 
stratified by illness seve rity only.13,39,52,55,77,81 Of those studies, 
43 (including 3229 indivi duals) reported duration of 
shedding in the upper respiratory tract (mean viral 
shedding duration 17·0 days [95% CI 15·5–18·6]; figure 2), 
seven (260 individuals) in the lower respiratory tract 
(14·6 days [9·3–20·0]; appendix p 6), 13 (586 individuals) in 
stool samples (17·2 days [14·4–20·1]; appendix p 7), and 
two (108 individuals) in serum sam ples (16·6 days 
[3·6–29·7]; appendix p 6). Maximum duration of RNA 
shedding reported was 83 days in the upper respiratory 
tract,35 59 days in the lower respiratory tract,27 126 days in 
stool samples,88 and 60 days in serum samples.78
Studies reporting duration of viral shedding in upper 
respiratory tract and stool samples were eligible for meta-
regression analysis. Pooled mean viral shedding duration 
was positively associated with age (slope 0·304 [95% CI 
0·115–0·493]; p=0·0016), but not sex (p=0·28; appendix 
pp 7–8). When adjusted for the propor tion of males in a 
multivariable analysis, mean age was positively associated 
with the mean duration of viral shedding in upper 
respiratory tract specimens (p=0·0029). There was a 
positive but non-significant association between mean age 
and duration of shedding in stool samples (p=0·37; 
appendix p 8).
Eight of 13 studies evaluating SARS-CoV-2 viral load in 
serial upper respiratory tract samples showed peak viral 
loads inferred from cycle threshold values within the first 
week of symptom onset.2–4,8,15–23 The highest viral loads were 
Figure 1: Study selection
MERS-CoV=Middle East respiratory syndrome coronavirus. SARS-CoV=severe acute respiratory syndrome 
coronavirus. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
948 records identified in 
MEDLINE and Embase
373 records identified from 
preprint servers 
1486 titles and abstracts screened 
350 records assessed for eligibility 
1136 excluded
 350 animal studies
 786 not relevant to this study
165 records identified from grey 
literature and additional 
papers identified through 
reference review   
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reported soon after or at the time of symptom onset,2,8,15,21,23 
or at day 3–5 of illness,3,4,20 followed by a consistent decline.
Five studies that evaluated viral load dynamics in lower 
respiratory tract samples observed a peak viral load in the 
second week of illness.3,4,17,21,23 By contrast, the dynamics of 
SARS-CoV-2 shedding in stool samples was erratic, with 
highest viral loads reported on day 7,17 2–3 weeks,22,23 and up 
to 5–6 weeks after symptom onset.21 Although two  studies 
reported significantly higher viral titres in stool samples 
than in respiratory samples,8,23 one study reported lower 
viral load in stool samples than in both lower and upper 
respiratory tract samples at the time of symptom onset.21
20 studies evaluated duration of viral RNA shedding 
based on disease severity. 13 of these studies reported 
Mean duration 
of viral shedding 
(95% CI), days 
SE
Fang et al (2020)29
Cai et al (2020)24
Hu et al (2020)35
Kim et al (2020)4
Le et al (2020)57
Lo et al (2020)68
Ling et al (2020)45
Qian et al (2020)71
Wu et al (2020)38
Xiao et al (2020)43
Xu et al (2020)36
Xu et al (2020)12
Yongchen et al (2020)34
Young et al (2020)20
Zhou et al (2020)40
Zhou et al (2020)33
Zhu et al (2020)82
Sakurai et al (2020)41
To et al (2020)58
Huang et al (2020)49 
Liang et al (2020)47
Shi et al (2020)31
Talmy et al (2020)42
Chen et al (2020)26
Hu et al (2020)53
Song et al (2020)75
Yang et al (2020)54
Wu et al (2020)79
Zhang et al (2020)22
Fu et al (2020)64
Tan et al (2020)17
Kujawski et al (2020)16
Yan et al (2020)37
Yang et al (2020)81
Xu et al (2020)80
Huang et al (2020)21
Chen et al (2020)25
Chang et al (2020)61
Li et al (2020)66
Pongpirul et al (2020)70
Tan et al (2020)10
Wang et al (2020)77
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Figure 2: Pooled mean duration (days) of SARS-CoV-2 shedding from the upper respiratory tract (random-effects model)
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
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longer duration of viral shedding in patients with severe 
illness than in those with non-severe illness,17,23–34 whereas 
five studies in upper respiratory tract samples16,18,35–37 and 
one study in stool samples38 reported similar shedding 
durations according to disease severity. One study 
reported shorter duration of viral shedding in moderate 
to severe illness than in mild to moderate illness.39 
Six studies compared viral shedding among individuals 
with severe illness versus non-severe illness:17,23,25,26,36,37 five 
studies showed significantly longer duration of shedding 
among those with severe illness than among those with 
non-severe illness,17,23,25,26,36 and one study observed no 
difference37 (table 1).
All but one study40 that examined the effect of age on 
SARS-CoV-2 shedding identified an association between 
older age (older than 60 years) and prolonged viral RNA 
shedding.23,24,26,31,35–37,41–43 Three studies identified age as an 
independent risk factor for delayed viral clearance.23,24,36 
Male sex was also associated with prolonged shedding,23,36,44 
and the association remained significant even when 
patients were stratified based on illness severity.23,36 
Corticosteroid treatment was associated with delayed viral 
clearance in four studies,31,36,45,46 and one study that 
recruited 120 patients with critical illness found no 
difference between corticosteroid and control groups.47
A randomised, placebo-controlled trial of remdesivir in 
adults with severe COVID-19 found a similar decline in 
viral load over time in remdesivir and control groups, as 
well as similar proportions of patients with undetectable 
viral RNA at 28 days.102 In a phase 2, open-label study 
evaluating interferon beta-1b, lopinavir–ritonavir, and 
ribavirin, a shorter duration of viral shedding was seen 
with combination treatment than with the control.48 
None of the antiviral regimens (chloroquine, oseltamivir, 
arbidol, and lopinavir–ritonavir) indepen dently improved 
viral RNA clearance.26,49 In a retrospective study of 
284 patients, lopinavir–ritonavir use was associated with 
delayed viral clearance even after adjusting for 
confounders.26
12 studies reported viral load dynamics or duration of 
viral shedding among individuals with asymptomatic 
SARS-CoV-2 infection (table 2); two demonstrated lower 
viral loads among asymptomatic individuals than 
among symptomatic individuals,8,50 and four found 
similar initial viral loads.13,14,51,52 However, Chau and 
colleagues reported significantly lower viral load in 
asymptomatic individuals during the follow-up than in 
symptomatic individuals.51 Faster viral clearance was 
observed in asymptomatic individuals in five of 
six studies.13,26,51,53,54 The exception, Yongchen and 
colleagues, found longer shedding dura tion among 
asymptomatic cases, but the difference was not 
significant.34
We identified 11 studies that attempted to isolate live 
virus. All eight studies that attempted virus isolation in 
respiratory samples successfully cultured viable virus 
within the first week of illness.3,9,16,52,55–58 No live virus was 
isolated from any respiratory samples taken after day 8 of 
symptoms in three studies,3,55,56 or beyond day 9 in 
two studies16,52 despite persistently high viral RNA loads. 
One study demonstrated the highest probability of posi-
tive culture on day 3 of symptoms.55 Arons and colleagues 
cultured viable virus 6 days before typical symptom onset; 
however, onset of symptoms was unclear.52
The success of viral isolation correlated with viral 
load quantified by RT-PCR. No successful viral culture 
was obtained from samples with a viral load below 
1 × 10⁶ copies per mL in one study,3 cycle threshold 
values higher than 24 in another study,55 or higher 
than 34 in other studies,52,56 with culture positivity 
declining with increasing cycle threshold values.56 
Several other studies cultured live virus from RT-PCR-
positive specimens; however, they did not correlate 
these results with viral load titres.9,57,58
One study reported the duration of viable virus shed ding 
in respiratory samples; time to clearance from symptom 
onset was 3–12 days in upper respiratory tract samples and 
5–13 days in lower respiratory tract samples, and no 
positive viral culture was obtained after day 4 in upper 
respiratory tract infection and day 8 in lower respiratory 
tract infection.3 Arons and colleagues cultured viable virus 
from the respiratory tract in one of three asymptomatic 
cases.52
Viral culture was successful in two of three 









Viral dynamics in patients with 
severe illness vs those with 
non-severe illness
p value
Chen et al 
(2020)25
ICU vs non-ICU 
patients
11 (95% CI 10–12) Median time to viral clearance 
significantly longer in ICU vs non-ICU 
patients (HR 3·17, 95% CI 2·29–4·37)
Only HR 
provided





12 (8–16) Shedding duration varies by severity: 
asymptomatic 6 days; mild 10 days; 
moderate 12 days; serious 14 days; 
critical 32 days
<0·0001










Viral shedding significantly longer 
in patients with severe illness: any 
sample 23 days vs 20 days (note that 




Xu et al 
(2020)36
WHO criteria 17 (13–32) Higher proportion of patients with 
severe illness had shedding >15 days 
(34·2% vs 16·2%)
0·049





23 (18–32) No difference in shedding duration 
(general illness 23 days vs severe illness 
26 days vs critical illness 28 days)
0·51








Shedding duration significantly longer 
in patients with severe illness 
(21 vs 14 days) in respiratory samples; 
no difference in shedding duration 
in stool or serum samples
0·04
CDC=Center for Disease Control and Prevention. HR=hazard ratio. ICU=intensive care unit. SARS-CoV-2=severe acute 
respiratory syndrome coronavirus 2. *IQR unless otherwise stated. 
Table 1: Severity of illness and viral dynamics
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from symptom onset were not reported.59 Andersson and 
colleagues were unable to culture virus from 27 RT-PCR-
positive serum samples.60
Of eight studies on SARS-CoV, none reported mean or 
median duration of viral shedding and thus were not 
eligible for quantitative analysis. The maximum duration 
of viral shedding reported was 8 weeks in upper respira-
tory tract,83,84 52 days in lower respiratory tract,83,85 
6–7 weeks in serum,86 and 126 days in stool samples.83,85,87–89 
Studies that evaluated SARS-CoV kinetics found low 
viral load in the initial days of illness, increasing after the 
first week of illness in upper respiratory tract samples, 
peaking at day 10,90 or days 12–14,87 and declining after 
weeks 3–4.84 High viral loads correlated with severity of 
illness and poor survival.84 Although Chen and colleagues 
identified an association between younger age and lower 
viral titres,84 Leong and colleagues found no difference.89 
Viable SARS-CoV was isolated from stool and respiratory 
samples up to 4 weeks, and urine speci mens up to 
day 36 from symptom onset.83,86 All attempts to isolate 
virus from RT-PCR-positive stool specimens collected 
more than 6 weeks after disease onset failed.85 The 
isolation proba bility for stool samples was approx-
imately five to ten times lower than for respiratory 
specimens.83
We identified 11 studies on MERS-CoV. Three studies 
(324 participants) reporting MERS-CoV shedding in the 
upper respiratory tract99–101 and four studies (93 participants) 
reporting MERS-CoV shedding in the lower respiratory 
tract91,92,96,101 were included in the quantitative analysis. The 
mean shedding duration was 15·3 days (95% CI 
11·6–19·0) in the upper respiratory tract and 16·3 days 
(13·8–18·9) in the lower respiratory tract (figures 3, 4). 
Only one study reported duration of viral shedding in 
serum with a maximum of 34 days.91 In a small study, 
mortality was higher in patients with viraemia (viral RNA 
in blood).92 In upper and lower respiratory tract speci-
mens, prolonged shedding was associated with illness 
severity93,94 and survival,95 with the shortest duration 
observed in asymp tomatic individuals.93 Peak viral loads 
were observed between days 7 and 10, and higher viral 
loads were observed among patients with severe illness 
and fatal outcome.91,93,94,96,97 Differences in viral loads 
between survivors and fatal cases was more pronounced 
in the second week of illness (p=0·0006).97 The proportion 
of successful viable culture was 6% in respiratory samples, 
with a viral load value below 1 × 10⁷ copies per mL.98
All but 11 studies (six cohort studies, two cross-sectional 
studies, and one randomised controlled trial on 
SARS-CoV-2 and two cohort studies on MERS-CoV) were 
case series, the majority of which recruited non-consecutive 
patients and were therefore prone to possible selection 
bias (appendix pp 9–13).
Discussion
This systematic review and meta-analysis provides 
comprehensive data on the viral dynamics of SARS-CoV-2, 
including the duration of RNA shedding and viable virus 
isolation. Our findings suggest that, although patients 
with SARS-CoV-2 infection might have prolonged RNA 
shedding of up to 83 days in upper respiratory tract 
infection, no live virus was isolated from culture beyond 
day 9 of symptoms despite persistently high viral RNA 
loads. This finding is supported by several studies 
demonstrating an association between viral load and 
viability of virus, with no successful culture from samples 
below a certain viral load threshold. These findings 







Viral dynamics in asymptomatic 
vs symptomatic individuals
p value
Arons et al 
(2020)52
Not reported No difference in viral load Not reported
Chau et al 
(2020)51
Not reported Initial viral load similar; asymptomatic individuals 
had significantly lower viral load during follow-up 
and faster viral clearance than symptomatic 
individuals
0·027
Chen et al 
(2020)26
6 (4–10) Significantly shorter duration of viral shedding 
among asymptomatic cases, with increasing 
shedding duration associated with increasing 
illness severity
<0·0001
Han et al 
(2020)8
Not reported Symptomatic children had higher initial RNA 
load in nasopharyngeal swab specimens than 
asymptomatic children (9·01 vs 6·32 log10 copies 
per mL)
0·048
Hu et al 
(2020)53
6 (2–12) Asymptomatic individuals had shorter duration 
of viral shedding compared with pre-symptomatic 
individuals (median duration of viral shedding was 
6 days [2–12] vs 12 days [12–14])
Not reported
Lavezzo et al 
(2020)14
Not reported No difference in viral load p=0·62 (E gene); 
p=0·74 (RdRp 
gene) 
Le et al 
(2020)57
9 Not reported Not applicable
Sakurai et al 
(2020)41
9 (6–11) Not reported Not applicable
Yang et al 
(2020)54
8 (3–12) Significantly shorter duration of viral shedding 
from nasopharynx swabs was observed among 




18 (range 5–28) Longer shedding duration among asymptomatic 
cases (median 18 days [range 5–28]) vs 
non-severe (10 days [2–21]) and severe (14 days 
[9–33]) cases
Not reported
Zhang et al 
(2020)13
9·6 Initial viral load similar; viral clearance occurred 
earlier in the asymptomatic (9·6 days) and 
symptomatic individuals (9·7 days), 
vs pre-symptomatic group (13·6 days)
<0·05
Zhou et al 
(2020)50
Not reported Significantly higher viral load in symptomatic 
(n=22) vs asymptomatic (n=9) individuals (median 
cycle threshold value 34·5 [IQR 37·5–39·5] vs 
39·0 [32·2–37·0]), but duration of shedding was 
similar
Not reported
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. *IQR, if available, unless otherwise stated. 
Table 2: SARS-CoV-2 viral dynamics in asymptomatic individuals compared with symptomatic 
individuals
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be indicated to deem patients no longer infectious. 
Duration of infectiousness and subsequent isolation 
timelines could reflect viral load dynamics and could be 
counted from symptom onset for 10 days in non-severe 
cases.
SARS-CoV-2 viral load appeared to peak in the upper 
respiratory tract within the first week after symptom 
onset, and later in the lower respiratory tract. By contrast, 
the viral load of SARS-CoV peaked at days 10–14 of illness 
and that of MERS-CoV peaked at 7–10 days of illness. 
Combined with isolation of viable virus in respiratory 
samples primarily within the first week of illness, patients 
with SARS-CoV-2 infection are likely to be most infectious 
in the first week of illness, emphasising the importance 
of immediate isolation with symptom onset early in the 
course of illness. Several studies report viral load peaks 
during the prodromal phase of illness or at the time of 
symptom onset.2–4,8,15–21 providing a rationale for the 
efficient spread of SARS-CoV-2. This finding is supported 
by the observation in contact-tracing studies that the 
highest risk of transmission occurs very early in the 
disease course (a few days before and within the first 
5  days after symptom onset).103,104 Although modelling 
studies estimated poten tial viral load peak before 
symptom onset, we did not identify any study that 
confirms pre-symptomatic viral load peak.15
Similar to SARS-CoV, SARS-CoV-2 can be detected in 
stool samples for prolonged periods, with high viral loads 
detected even after 3 weeks of illness. In SARS-CoV, RNA 
prevalence in stool samples was high, with almost all 
studies reporting shedding in stools. Although viable 
SARS-CoV was isolated during up to 4 weeks of illness, 
faecal–oral transmission was not considered to be a 
primary driver of infection. By contrast, none of the 
studies in MERS-CoV reported duration of viral shedding 
in stool samples and RNA detection was low.97,105 So far, 
only a few studies have demonstrated viable SARS-CoV-2 
in stool samples.59,106 Thus, the role of faecal shedding in 
viral transmission remains unclear.
Viral loads appear to be similar between asymptomatic 
and symptomatic individuals infected with SARS-CoV-2. 
Nevertheless, most studies demonstrate faster viral 
clearance among asymptomatic individuals than those 
who are symptomatic. This finding is in keeping with viral 
kinetics observed with other respira tory viruses such as 
influenza and MERS-CoV, in which people with 
asymptomatic infection have a shorter dura tion of viral 
shedding than symptomatic individuals.93,107 However, data 
on the shedding of infectious virus in asymptomatic 
individuals are too scarce to quantify their transmission 
potential in order to inform policy on quarantine duration 
in the absence of testing.
To our knowledge, this is the first systematic review to 
comprehensively examine and compare SARS-CoV-2, 
SARS-CoV, and MERS-CoV viral dynamics, and the first 
meta-analysis of viral shedding duration. Our study has 
limitations. First, almost all patients in the included 
studies received a range of treatments, which might have 
modified the shedding dynamics. Second, our meta-
analysis identified substantial study heterogeneity, 
probably due to differences in study population, 
follow-up, and management approaches. Furthermore, 
shedding duration is reported as median with IQR for 
most studies, but meta-analysis necessitates conversion 
to mean with SD.6 The validity of this conversion is based 
on the assumption that duration of viral shedding is 
normally distributed, which might not apply to some 
studies. Last, although there is probably a broad overlap, 
the true clinical window of infectious shedding might 
not entirely align with viral culture duration.
We identified a systematic review of SARS-CoV-2 viral 
load kinetics that included studies published up until 
May 12, 2020.108 This review included 26 case reports and 
13 case series involving less than five individuals, which 
did not meet our eligibility criteria; these studies are prone 
to substantial selection bias, reporting atypical cases with 
prolonged viral shedding. Additionally, the review 
included studies that reported viral shedding duration 
from the time of hospital admission or initial PCR 
positivity. Furthermore, no meta-analysis of the duration 
of viral shedding was done.
This review provides detailed understanding about the 
evidence available so far on viral dynamics of SARS-CoV-2 
and has implications for pandemic control strategies and 
infection control practices. Although SARS-CoV-2 RNA 
shedding can be prolonged in respiratory and stool 
Figure 3: Pooled mean duration (days) of MERS-CoV shedding from the upper respiratory tract 
(random-effects model)
MERS-CoV=Middle East respiratory syndrome coronavirus.
Mean duration 
of viral shedding 
(95% CI), days 
Al-Jasser et al (2019)99
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Duration of viral shedding (days)
Figure 4: Pooled mean duration (days) of MERS-CoV shedding from the lower respiratory tract (random-
effects model)
MERS-CoV=Middle East respiratory syndrome coronavirus.
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samples, viable virus is short-lived, with culture success 
associated with viral load levels. Most studies detected 
the SARS-CoV-2 viral load peak within the first week of 
illness. These findings highlight that isolation practices 
should be commenced with the start of first symptoms, 
including mild and atypical symptoms that precede more 
typical COVID-19 symptoms. However, given potential 
delays in the isolation of patients, effective containment 
of SARS-CoV-2 might be challenging even with an early 
detection and isolation strategy.109
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